Pseudomonas aeruginosa susceptibility in a university hospital: Recognition and treatment

J. C. Rotschafer, L. R. Shikuma

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Pseudomonas aeruginosa continues to be a leading cause of nosocomial bacteremia and other serious, often life-threatening infections. The incidence of P. aeruginosa infection appears to be increasing. The resilience of Pseudomonas in the hosptial environment, its endogenous virulence factors, and its current level of resistance to antimicrobials make it a formidable pathogen, particularly in a compromised host. Despite the availability of several effective antipseudomonal antibiotics, infections caused by this pathogen are still associated with significant morbidity and mortality. Early recognition and prompt intervention with appropriate antimicrobial agents are vital to successful management. Combination therapy with an aminoglycoside and an extended-spectrum penicillin or cephalosporin is recommended in the initial mangement of suspected or documented P. aeruginosa infections.

Original languageEnglish (US)
Pages (from-to)575-581
Number of pages7
JournalDrug Intelligence and Clinical Pharmacy
Issue number7-8
StatePublished - 1986


Dive into the research topics of 'Pseudomonas aeruginosa susceptibility in a university hospital: Recognition and treatment'. Together they form a unique fingerprint.

Cite this